AI Tool

Xyntha Review

Xyntha is a recombinant antihemophilic factor used for the treatment and prophylaxis of bleeding in individuals with Hemophilia A.

shipped Aug 26, 2026freemium

Why it matters

1Indicated for on-demand treatment, perioperative management, and routine prophylaxis of Hemophilia A.

2Effective in controlling bleeding episodes, with 94% of episodes in children resolving with 1-2 infusions in clinical studies.

3Routine prophylactic treatment reduced mean annualized bleed rate by 88% in patients 12 years and older.

4Available in a Prefilled Dual-Chamber Syringe for easier administration, with a 3,000 IU dose launched in August 2026.

About Xytha

Platforms

Windows

overview

What is Xyntha?

Xyntha is a pharmaceutical product developed by Pfizer that enables individuals with Hemophilia A to manage and prevent bleeding episodes. It is a recombinant, or man-made, clotting factor replacement therapy specifically indicated for use in adults and children with Hemophilia A (congenital factor VIII deficiency or classic hemophilia). Xyntha works by temporarily replacing the missing factor VIII protein, which is essential for blood clotting. It is not indicated for patients with von Willebrand's disease.

features

Key Features of Xyntha

Xyntha's primary features revolve around its therapeutic action as a recombinant factor VIII product for Hemophilia A.

Recombinant Factor VIII Replacement: Provides a man-made version of the missing clotting factor VIII.
On-Demand Treatment: Used for the control and resolution of acute bleeding episodes.
Perioperative Management: Administered to manage bleeding during and after surgical procedures.
Routine Prophylaxis: Utilized to reduce the frequency of bleeding episodes in patients.
Prefilled Dual-Chamber Syringe: Facilitates easier and faster administration by combining powder and diluent (available for 3,000 IU dose as of August 2026).
FDA Approved: Approved by the U.S. Food and Drug Administration for its indicated uses, including prophylaxis (August 2020).

use cases

Who Should Use Xyntha?

Xyntha is prescribed for specific patient populations with Hemophilia A, based on clinical indications.

Adults and Children with Hemophilia A: For the treatment of congenital factor VIII deficiency.
Patients Experiencing Bleeding Episodes: For on-demand control of acute bleeds.
Patients Undergoing Surgery: For perioperative management to prevent excessive bleeding.
Patients Requiring Prophylaxis: For routine administration to reduce the frequency of bleeding episodes.

how to use

How to Use Xyntha

Xyntha is administered intravenously after reconstitution. The dosage and frequency depend on the patient's weight, severity of Hemophilia A, and the specific use case (on-demand, perioperative, or prophylaxis).

1Reconstitute the Xyntha powder with the provided diluent, following aseptic techniques.
2For the Prefilled Dual-Chamber Syringe, follow specific instructions for mixing the powder and diluent within the syringe.
3Administer the reconstituted solution intravenously over several minutes.
4Monitor for efficacy in controlling bleeding or for prophylactic effect.
5Be aware of potential side effects such as headache, joint pain, fever, cough, and the possibility of inhibitor development.

pricing

Xyntha Pricing & Plans

The cost of Xyntha is subject to variations based on pharmacy, insurance coverage, and specific dosage requirements. As of January 1, 2025, the list price for Xyntha and Xyntha Solofuse increased by 5.0%. The Wholesale Acquisition Cost (WAC) for Xyntha and Xyntha Solofuse kits was $1.82 per unit as of May 1, 2024. Retail pricing observed via GoodRx in August 2026 indicated costs around $500-$550 for a single kit, while Drugs.com noted a cost of approximately $6 for a kit for cash-paying customers, highlighting significant variability.

Wholesale Acquisition Cost (WAC): $1.82 per unit (as of May 1, 2024)
Retail Pricing: Approximately $500-$550 for 1 kit (GoodRx, August 2026)
Retail Pricing: Approximately $6 for 1 kit (Drugs.com, cash-paying customers)

Pros

+Effective in controlling bleeding episodes, with high success rates in clinical trials (94% in children, 93% in adults).
+Reduces annualized bleed rates significantly (88% reduction with prophylaxis).
+Approved for a range of uses including on-demand, perioperative, and prophylactic treatment.
+New Prefilled Dual-Chamber Syringe (August 2026) simplifies reconstitution and administration.
+Established treatment option from a major pharmaceutical company (Pfizer).

Cons

−Requires intravenous administration, which can be inconvenient.
−Potential for serious allergic reactions, including anaphylaxis.
−Risk of developing inhibitors (neutralizing antibodies) to factor VIII, which can reduce treatment effectiveness.
−Common side effects include headache, joint pain, fever, and cough.
−Higher rate of injection site reactions compared to some competitors like Afstyla.
−Not an extended half-life product, potentially requiring more frequent dosing than newer EHL alternatives.

Similar Tools

Xyntha vs Competitors

Xyntha operates within a competitive landscape of recombinant factor VIII products for Hemophilia A. The market includes both standard half-life and extended half-life (EHL) products, as well as non-factor therapies.

Hyperledger Aries Cloud Agent - Python (ACA-Py)↗

Provides a comprehensive framework for building decentralized identity agents, including DIDComm, verifiable credential issuance, and verification, designed for developers.

While Xytha focuses on a local 'workbench' without full agent execution, ACA-Py offers the underlying, modular components and protocols that such a workbench would interact with or demonstrate. It requires more setup as a framework but provides deeper control over SSI logic.

DIF Universal Resolver↗

A standardized, open-source tool for resolving Decentralized Identifiers (DIDs) across many different DID methods into DID documents.

Xytha includes DID inspection and verification. The Universal Resolver directly addresses the 'inspect versions' and 'verify credentials' aspects by providing the core mechanism to resolve DIDs, which is fundamental to verifying credentials. It's a more focused tool specifically for DID resolution.

walt.id↗

Offers an open-source stack for issuing, holding, and verifying verifiable credentials and building wallets, with alignment to EU Digital Identity Wallet standards.

walt.id provides a broader open-source stack for the entire verifiable credential lifecycle (issuance, holding, verification) compared to Xytha's focus on local identity and proof verification. It offers more comprehensive building blocks for developers to create their own SSI solutions.

SpruceID↗

Provides open-source libraries and SDKs for credential issuance, verification, and wallet building, with a strong focus on standards-first tooling.

Similar to walt.id, SpruceID offers open-source developer tools for building SSI components, covering issuance and verification. It provides a modular approach for developers to integrate specific SSI functionalities, whereas Xytha is presented as a more integrated 'workbench' application.

See every Xytha alternative, compared→

Related AI Tools

Other tools in this category, matched by shared tags

Reussitess®971 ScheduleToCalendar FindAnySoftware UnitRouter CuspHub GuardAgent

Visit Xytha↗